in

Roy Jacobs & Associates Investigating Refusal of Emulex Corp. to Negotiate Potential Buyout

NEW YORK, April 21, 2009 (LAWFUEL) — Roy Jacobs & Associates is
investigating potential shareholder claims in connection with Broadcom
Corp.’s offer to purchase Emulex Corp. (NYSE:ELX) for $9.25 per share
and Emulex apparent unwillingness to entertain the offer or seek to
maximize shareholder value. Rather it has been reported that Emulex has
adopted a poison pill defense to prevent the Company from being
acquired, and as a possible tool to entrench management in violation of
their fiduciary duties, which will prevent shareholders from realizing
top value for their shares, which could materially exceed Broadcom’s
current offer.

If you held Emulex shares as of April 20, 2009 and you are interested
in discussing your rights free of charge, please contact Roy L. Jacobs.
Mr. Jacobs will be glad to personally speak with you.

Low Income Taxpayer Clinic Grant Recipients Announced

US Law – Winston & Strawn’s McMickle Named Co-Chair of ABI Legislative Committee – US Bankruptcy News